Please login to the form below

Not currently logged in
Email:
Password:

The Research Partnership makes senior US appointments

Paul Dick joins from IMS Health and Phil Rosenberg arrives from BioVid

The Research Partnership Paul DickThe Research Partnership has bolstered its US team with the appointments of Paul Dick as vice president of business development and Phil Rosenberg as research director.

Dick (pictured right) joins the London-headquartered company from IMS Health, where he ran the global market measurement group for nine years as senior director of US sales.

Prior to that he served at Wyeth for four years as international market research manager.

Meanwhile, Rosenberg arrives at The Research Partnership from US-based research firm BioVid Corporation.

He has over 25 years' experience has previously held senior market research positions at companies such as GfK and @Futures.

The Research Partnership has also appointed Sarah Tax to its US office as a research executive from custom qualitative healthcare agency Karchner Marketing Research.

US president Harriet Kozak said: “We are delighted to welcome these talented individuals to the US team, particularly Paul and Phil who we have known for many years.

“We have been looking to expand our US operations and these appointments mean that we now have a team of 15 researchers based in our Philadelphia office. With these talented individuals on board, we look forward to consolidating our US business and making new client acquisitions in both global and domestic research.”

12th September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics